表紙
市場調查報告書

生物製劑API (原料藥) 生產服務 - 全球產業、市場展望 (∼2029年) :哺乳類細胞培養、微生物發酵、人類成長賀爾蒙、胰島素、干擾素、單株抗體、疫苗

Biological Drug API Manufacturing Services World Industry and Market Forecast to 2029: Mammalian Cell Cultures, Microbial Fermentations, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccines, Others

出版商 Visiongain Ltd 商品編碼 927103
出版日期 內容資訊 英文 211 Pages
商品交期: 最快1-2個工作天內
價格
生物製劑API (原料藥) 生產服務 - 全球產業、市場展望 (∼2029年) :哺乳類細胞培養、微生物發酵、人類成長賀爾蒙、胰島素、干擾素、單株抗體、疫苗 Biological Drug API Manufacturing Services World Industry and Market Forecast to 2029: Mammalian Cell Cultures, Microbial Fermentations, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccines, Others
出版日期: 2019年11月07日內容資訊: 英文 211 Pages
簡介

生物製劑API (原料藥) 生產市場推估在預測期間的前半會成長9.5%的CAGR。 在2018年,哺乳類細胞培養系統,成為了生物製劑API製造產業最大的次級市場。

本報告分析了全球生物製劑的API (活性藥物成份) 承包生產服務市場,並統整了市場的基本結構和最新情勢、主要市場促進及抑制要素、全球整理及領域別、地區別的市場趨勢預測、主要企業的檔案及事業策略、業界向心力 (SWOT分析)、未來的技術開發、市場成長的方向性等資訊。

第1章 報告概要

第2章 生物製劑API (原料藥) 生產服務:簡介

  • 什麼是生物製劑API (原料藥) 生產服務?
    • 生物製劑API的生產:生產工程的概要
    • 生物製劑API生產市場的定義
    • 用於API生產的各項發現
  • 生物製劑API的生產上的課題
  • 外包:生物製劑API生產服務的一般趨勢
  • 生物製劑API生產服務市場的未來趨勢

第3章 生物製劑API (原料藥) 生產服務:全球市場展望、預測

  • 生物製劑API承包生產服務市場業績 (最新值)
    • 業績預測
  • 生物製劑API生產服務市場的促進及抑制要素
    • 市場促進要素
    • 市場抑制要素
  • 生物製劑API生產服務市場的未來展望:需求擴大

第4章 生物製劑API生產服務的次級市場:全球市場展望、預測、發現系統

  • 次級市場
    • 哺乳類細胞培養
    • 微生物發酵
    • 為其開發中的API發現系統
  • 本章概要:市場正成長

第5章 生物製劑API生產服務市場:生物製劑API承包生產的主要部門展望

  • 免疫療法:生物製劑API承包生產的最大部門 (概要)
    • 單株抗體API承包生產部門:市場預測
    • 單株抗體API承包生產部門:未來展望
  • 疫苗API承包生產:對CMO有潛力的市場機會
    • 疫苗API承包生產市場:展望與預測
    • 疫苗生產上的課題
  • 胰島素療法:市場概要與API承包生產市場的展望
    • 胰島素類似物API承包生產市場的預測
    • 胰島素類似物市場預測:公司自製抑制了胰島素治療藥物API承包生產市場的成長
    • 胰島素API承包生產市場的發展趨勢
  • 干擾素治療藥物:簡介、API承包生產市場的展望
    • 干擾素治療藥物API承包生產市場的預測
    • 市場機會的預測
  • 成長賀爾蒙:簡介、API承包生產市場的展望
    • 成長賀爾蒙API承包生產市場的預測
    • 現在大半是公司自製
    • 長時間作用型治療藥物為外包提供機會
  • 本章摘要:主要生物製劑產品的外包預測

第6章 主要國家的生物製劑API承包生產服務市場

  • 全球生物製劑API生產服務市場:地區別細項
  • 北美洲
  • 歐盟
  • 北美洲
  • 金磚國家
  • 其他主要國家
  • 本章摘要

第7章 生物製劑API生產服務市場:主要CMO (醫藥品委託製造機構)

  • 前4大公司引領市場
  • 主要企業:生產能力別
    • 小規模企業佔了大半
    • 加入市場的主要障礙
  • FDA (美國食品藥品監督管理局) 去除了生物仿製市場的障礙
  • Boehringer Ingelheim BioXcellence
    • 策略展望:強化亞洲市場
  • Celltrion:亞洲生物製劑市場的領袖
    • 在夥伴關係與合併事業的道路上前進
  • Patheon NV:合併及收購成為目標
  • Lonza:全球最高的細胞培養能力
    • 作為成長策略的生物製劑領域的核心勝任力
  • 其他應矚目的企業
    • Samsung BioLogics:強化生物仿製
    • Cytovance Biologics:事業拓展計劃
    • Fujifilm Diosynth Biotechnologies:擴充未來設備、服務
  • 經營CMO部門的代表性生物醫藥品企業
    • AbbVie Contract Manufacturing:透過收購企業強化競爭力
    • GSK Biopharmaceuticals
    • Sandoz:生物製劑、生物仿製的專門企業
    • Rentschler Biotechnologie:近來拓展業務的動向
    • Teva:生物製劑市場中未來有潛力的企業
    • Catalent:透過業務合作,提供新的平台
  • 本章摘要;主要企業的動向趨勢

第8章生物製劑API生產服務市場產業趨勢:定性分析

  • SWOT分析:生物製劑API生產服務市場的優缺點
  • STEP分析
  • 生物製劑的開發趨勢
    • 生物仿製:對CMO來說很重要的市場機會
    • 投資新一代型抗體開發的CMO
    • 罕用藥、個人化醫療:貼片小型化的趨勢
    • 拋棄式 (單次使用) API產品的市場的未來展望
    • 生物製劑API生產的外包趨勢
  • 對生物製劑API生產服務的法規及影響
  • 本章摘要

第9章 結論

  • 市場
  • 市場展望
  • 市場成長

附錄

目錄
Product Code: PHA0550

The biological drug API manufacturing market is estimated to grow at a CAGR of 9.5% in the first half of the forecast period. In 2018, Mammalian cell culture systems submarket represents the largest submarket within the biological drug API manufacturing industry.

How this 211-page report delivers:

Biological Drug API Manufacturing Services market forecast to 2029

Biological Drug API Manufacturing Services market forecast to 2029 by Expression Systems:

  • Mammalian cell culture
  • Microbial fermentation
  • Other expression platforms

Biological Drug API Manufacturing Services market forecast to 2029 by Therapeutic Area:

  • Monoclonal antibody (mAb) therapies
  • Vaccines
  • Insulin therapies
  • Interferon therapies
  • Growth hormones
  • Other Therapeutic Areas

Biological Drug API Manufacturing Services market forecast to 2029 by Regional and National Market:

  • North America: US, Canada
  • Europe: Germany, France, the UK, Switzerland, Spain, Italy, Rest of Europe
  • BRIC: Brazil, Russia, China, India
  • Japan
  • South Korea
  • Singapore
  • RoW

Profiles leading companies that offer biotech API manufacturing services to the pharmaceutical industry. Leading CMOs profiled in this report are:

  • Abbvie
  • Boehringer Ingelheim BioXcellence
  • Catalent
  • Celltrion
  • Cytovance Biologics
  • Fujifilm Diosynth Biotechnologies
  • GSK
  • Lonza
  • Patheon N.V.
  • Rentschler Biopharma
  • Samsung BioLogics
  • Sandoz
  • Teva

Provides qualitative analysis: SWOT and STEP Analysis of the biological drug API manufacturing market.

Key questions answered by this report:

  • How is the biological drug API manufacturing services market evolving?
  • What is driving and restraining the biological drug API manufacturing services market?
  • What are the market shares of each main segment of the overall biological drug API manufacturing services market in 2018?
  • How will each main biological drug API manufacturing services submarket grow over the forecast period and how much revenue will these submarkets account for in 2029?
  • How will the market shares for biological drug API manufacturing services submarkets develop from 2019 to 2029?
  • What will be the main drivers for the overall market from 2019 to 2029?
  • How will political and regulatory forces influence the regional markets and submarkets?
  • Will leading national biological drug API manufacturing services markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2029 and which countries will lead the market in 2029?
  • Who are the leading companies and what are their prospects?
  • What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?
  • How will the industry evolve during the period 2019 to 2029, and which trends will be important?

Visiongain's study is intended for anyone requiring commercial analyses for the biological drug API manufacturing market. You find data, trends and predictions.

Buy our report today Biological Drug API Manufacturing Services World Industry and Market Forecast to 2029: Mammalian Cell Cultures, Microbial Fermentations, and Other Expression Systems; Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccines, and Others Therapeutic Areas.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Contract Biological Drug API Manufacturing: World Market Review 2018
  • 1.2. Benefits of this Report
    • 1.2.1. How This Report Delivers
    • 1.2.2. Main Questions Answered by This Analytical Report
  • 1.3. Who is This Report For?
  • 1.4. Methods of the Study
  • 1.5. Frequently Asked Questions (FAQ)
  • 1.6. Associated Reports
  • 1.7. About Visiongain

2. Introduction to Biological Drug API Manufacturing Services

  • 2.1. What are Biological Drug API Manufacturing Services?
    • 2.1.1. Producing Biological drug API: An Overview of the Manufacturing Process
    • 2.1.2. Defining the Biological Drug API Manufacturing Market
    • 2.1.3. Differing Expression Systems to Manufacture APIs
  • 2.2. Challenges in Manufacturing Biological drug API
  • 2.3. Outsourcing: A Common Trend in Biological Drug API Manufacturing Services
  • 2.4. Future Trends for the Biological Drug API Manufacturing Services Market

3. Biological Drug API Manufacturing Services: World Market Outlook and Forecast 2019-2029

  • 3.1. The Contract Biological Drug API Manufacturing Services Market Performance, 2018
    • 3.1.1. Contract Biological Drug API Manufacturing Services: Forecast 2018-2029
  • 3.2. Drivers and Restraints in the Biological Drug API Manufacturing Services Market
    • 3.2.1. Drivers in the Biological Drug API Manufacturing Market
      • 3.2.1.1. The Ageing Population is a Driver for Growth
      • 3.2.1.2. The Patent Cliff Effect Will Stimulate Biologics and Biosimilar Development
      • 3.2.1.3. Outsourcing as a Driver for Growth
      • 3.2.1.4. Opportunities from the Long Pipeline Will Drive Growth
      • 3.2.1.5. Increased Investment in Orphan Drugs from Companies
      • 3.2.1.6. Emerging Markets Will Grow and Influence the Market
      • 3.2.1.7. Technological Changes: Single-Use Technology Will Become Essential in the Next 10 Years
    • 3.2.2. Restraints on Growth in the Biological Drug API Manufacturing Services Market
      • 3.2.2.1. Pricing Pressures Will Limit Market Growth
      • 3.2.2.2. Regulatory Restrictions Will Increase
      • 3.2.2.3. Overcapacity Will Be Adverse to Market Growth for CMOs
      • 3.2.2.4. Complexity of API Production is a Challenge
  • 3.3. Outlook for the Outsourced Biological drug API Services: Increased Demand

4. Biological Drug API Manufacturing Services Submarket by Expression Systems: World Market Outlook and Forecasts 2019-2029

  • 4.1. Submarkets for the Biological Drug API Manufacturing Services Industry
    • 4.1.1. The Mammalian Cell Culture Submarket
      • 4.1.1.1. The Mammalian Cell Culture Submarket Forecast 2018-2029
      • 4.1.1.2. ADCs and Next-Generation Antibodies Will Drive Growth 2018-2029
    • 4.1.2. The Microbial Fermentation Submarket
      • 4.1.2.1. The Microbial Fermentation Submarket Forecast 2018-2029
      • 4.1.2.2. Increase in Demand for Insulin Will Drive Growth 2018-2029
    • 4.1.3. Other APIs Expression Systems Are Still in Development
      • 4.1.3.1. Plant-Made Pharmaceuticals
      • 4.1.3.2. Yeast Cell Expression Systems
      • 4.1.3.3. Insect Cell Expression Systems
      • 4.1.3.4. Other Expression Systems Submarket Forecast 2018-2029
  • 4.2. Chapter Summary: Positive Growth for the Market

5. Biological Drug API Manufacturing: Outlook for Leading Biological Drug Contract API Sectors: 2019-2029

  • 5.1. Antibody Therapies: An Introduction to the Largest Contract API Biological Drug Sector
    • 5.1.1. Contract API Monoclonal Antibody Manufacturing Forecast 2018-2029
    • 5.1.2. Outlook: Outsourced Manufacturing for Monoclonal Antibody APIs Will Increase
  • 5.2. Contract API Vaccine Manufacturing: A Promising Opportunity for CMOs
    • 5.2.1. Contract API Vaccine Market: Outlook and Forecast 2018-2029
    • 5.2.2. Challenges in Manufacturing Vaccines
  • 5.3. Introduction to the Insulin Therapies Market and Outlook for the Contract API Insulin Therapies Market
    • 5.3.1. Contract API Insulin Analogues Forecast 2018-2029
    • 5.3.2. Insulin Analogues: In-House Production Restrains Contract API Insulin Therapies Market Growth
    • 5.3.3. Development Trends in the Contract API Insulin Market 2018 to 2029
  • 5.4. Introduction to the Interferon Therapy Market and Outlook for the Contract API Interferon Therapy Market
    • 5.4.1. Contract API Interferon Market Forecast 2018-2029
    • 5.4.2. Unlikely to be Opportunities in the Contract API Interferon Market
  • 5.5. Introduction to the Growth Hormone Market and Outlook for the Contract API Growth Hormone Manufacturing Market
    • 5.5.1. Contract API Growth Hormone Market Forecast 2018 to 2029
    • 5.5.2. Most Manufacturing is In-House for Growth Hormone Production
    • 5.5.3. Long-Acting Therapies Provide Opportunity for Outsourcing
  • 5.6. Chapter Summary: Outsourcing for Key Biological Products 2018-2029

6. Leading National Markets for Contract Biological Drug API Manufacturing Services Market Forecast to 2029

  • 6.1. Regional Breakdown of the World Biological Drug API Manufacturing Services Market
    • 6.1.1. North America and EU Dominate Growth for Leading National Submarkets 2018-2029
    • 6.1.2. National Revenue Shares by 2029: Emerging Market Growth
  • 6.2. Contract Biological Drug API Manufacturing in EU Market 2018-2029
    • 6.2.1. Strong Growth for the EU Revenue Forecasts 2018-2029
    • 6.2.2. Forecasts for Switzerland and Leading EU National Revenues 2018-2029
      • 6.2.2.1. Germany Leads the EU Biotech Market with Strong Growth
      • 6.2.2.2. UK: Strong Research Sector Will Drive Market Growth
      • 6.2.2.3. France: Strong Vaccine Development Industry
      • 6.2.2.4. Switzerland: Headquarters for Leading Companies
      • 6.2.2.5. Spain: Numerous Biotech Companies
      • 6.2.2.6. Italy: Outlook and Forecast 2018-2029
  • 6.3. Contract Biological Drug API Manufacturing in North America Market 2018-2029
    • 6.3.1. Forecasts for North America Leading National Revenues 2018-2029
    • 6.3.2. US: A Market Leader in Biological Drug API Manufacturing
    • 6.3.3. Canada: A Market Leader in Biological Drug API Manufacturing
    • 6.3.4. Mexico: A Market Leader in Biological Drug API Manufacturing
  • 6.4. BRIC Market: Contract Biological Drug API Manufacturing Services Market 2018-2029
    • 6.4.1. Emerging Nations May Develop a Presence in the Biologics Market
    • 6.4.2. Increased Demand for Biosimilars and Biological Drugs 2018-2029
    • 6.4.3. China is Poised for Growth: Forecast for 2018-2029
    • 6.4.4. India Offers a Lower-Cost Advantage for Biological Drug API Manufacturing Services: Forecast 2018-2029
    • 6.4.5. Brazilian and Russian Governments Promoting Domestic Biotech Development
      • 6.4.5.1. Russian Biological Drug API Manufacturing Services Forecast: 2018-2029
      • 6.4.5.2. Brazilian Biological Drug API Manufacturing Services Forecast: 2018-2029
  • 6.5. Forecasts for the Other Leading Nationals Revenues 2018-2029
    • 6.5.1. Japan: A Less Mature Contract Manufacturing Market
    • 6.5.2. Leading CMOs Celltrion and Samsung BioLogics Drive the Market in South Korea: Market Forecast, 2018-2029
    • 6.5.3. Singapore: Market Forecast, 2018-2029
  • 6.6. Summary of Chapter: Outlook for Leading National Submarkets 2018-2029

7. Leading CMOs in the Biological Drug API Manufacturing Services Market

  • 7.1. Four Companies Led the Market in 2018
  • 7.2. Leading Companies by Capacity
    • 7.2.1. Small-Scale Biopharmaceutical Manufacturing is a Common Trend
    • 7.2.2. Barriers to Market Entry 2018-2029
      • 7.2.2.1. The High Cost of Facilities: Acquisition as a Cheaper Alternative
  • 7.3. FDA Opens Barriers for the Biosimilars Market
  • 7.4. Boehringer Ingelheim BioXcellence
    • 7.4.1. Strategic Outlook: Expanding into the Asian Market
  • 7.5. Celltrion: Biologics Leader in Asia
    • 7.5.1. Celltrion: Following Partnerships and Joint Ventures Path
  • 7.6. Patheon N.V.: Target for Mergers and Acquisitions
  • 7.7. Lonza Has the Largest Worldwide Cell Culture Capacity
    • 7.7.1. Lonza: Biopharmaceutical Core Competency as a Strategy for Growth
  • 7.8. Other Market Players of Interest in 2018
  • 7.9. Samsung BioLogics: Focusing on Biosimilars
    • 7.9.1. Samsung BioLogics: Partnership Strategy for Future Expansion
  • 7.10. Cytovance Biologics: Plans to Expand
  • 7.11. Fujifilm Diosynth Biotechnologies
    • 7.11.1. Facility and Service Expansion for the Future
  • 7.12. Leading Biopharma Companies Operate CMO Divisions
  • 7.13. AbbVie Contract Manufacturing: Strength through Acquisition
  • 7.14. GSK Biopharmaceuticals
  • 7.15. Sandoz: Expertise in Biologics and Biosimilars
  • 7.16. Rentschler Biopharma: Recent Expansions
  • 7.17. Teva: A Future Player in the Biologics Market
  • 7.18. Catalent: Follows Acquisition and Investment Strategy for Expansion

8. Biological Drug API Manufacturing Services Market Industry Trends: Qualitative Analysis

  • 8.1. SWOT Analysis: Strengths and Weaknesses of the Biological Drug API Manufacturing Services Market 2018
    • 8.1.1. Strength: Biopharmaceutical Demand for Outsourcing is increasing
    • 8.1.2. Weakness: A Fragmented Market with a Costly and Difficult Manufacturing Process
    • 8.1.3. Opportunities for the Biological Drug API Manufacturing Services Market 2018-2029
    • 8.1.4. Threats for the Biological Drug API Manufacturing Services Market 2018-2029
  • 8.2. STEP Analysis of the Biological Drug API Manufacturing Services Market
    • 8.2.1. Social Factors: Drug Pricing Pressures to Meet Demand for an Increasing Ageing Population
    • 8.2.2. Technological Factors: Advances Will Drive Growth
      • 8.2.2.1. Single-Use Technology: A Vital Trend for the Future
    • 8.2.3. Economic Factors: The High Cost of Manufacturing Will Lead to Outsourcing
    • 8.2.4. Political Factors: Regulatory Requirements Need to Be Met
  • 8.3. Trends in Biological Drug Development 2018-2029
    • 8.3.1. Biosimilars Will Be an Important Opportunity for CMOs
    • 8.3.2. CMOs are investing in Next-Generation Antibody Development
    • 8.3.3. Orphan Drugs and Personalised Medicine: Trend for Smaller Batches
    • 8.3.4. Outlook for Single-Use Technologies in Biological Drug API Manufacturing 2018-2029
      • 8.3.4.1. Future Direction: Single-Use Systems will be Essential
    • 8.3.5. Outsourcing Trends for Biological Drug API Manufacturing 2018-2029
      • 8.3.5.1. Biopharma Companies Continue to Invest in In-House Facilities
      • 8.3.5.2. Off-shoring Biological Drug API Manufacturing to Emerging Markets: Not a Trend for this Decade?
      • 8.3.5.3. Overcapacity is a Risk for the Biotech CMO Industry
      • 8.3.5.4. Future Trends: Strategic Partnering
      • 8.3.5.5. Alternative Expression Methods
  • 8.4. Regulations and Effects on the Biological Drug API Manufacturing Services Industry
    • 8.4.1. Effect on the Emerging Biological Drug API Manufacturing Services Market 2018-2029
    • 8.4.2. Regulations in Other Countries in the Biological drug API Market
  • 8.5. Chapter Summary: Industry Trends for Contract Biological Drug API Manufacturing to 2028

9. Conclusions

  • 9.1. The Contract Biological Drug API Manufacturing Services Market
  • 9.2. Outlook for the Biological Drug API Manufacturing Services Market
    • 9.2.1. Mammalian Cell Culture is the Leading Expression Platform for Outsourced Biological Drug API Manufacturing
    • 9.2.2. The US and EU Markets Lead for the Global Biological Drug API Manufacturing Services Market in 2017
    • 9.2.3. Single-Use Technology Will Become Indispensable for Success in the Market
  • 9.3. Growth in the Market 2018-2029
    • 9.3.1. The Future of the Biological Drug API Manufacturing Services Marketplace

Appendices

  • Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 2.1: Contract API Manufacturing: Revenues ($bn) and Market Share (%) by Sector, 2018
  • Table 3.1: Contract Biological Drug API Manufacturing Services Market: Overall Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 4.1: Contract Biological Drug API Manufacturing Services Market Revenue Forecasts by Expression Systems Submarket ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 4.2: Contract Biological Drug API Manufacturing Services Market Revenue Forecasts for Mammalian Cell Culture Submarket ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 4.3: ADC Pipeline 2019
  • Table 4.4: Recent ADC's Investment
  • Table 4.5: Contract Biological Drug API Manufacturing Services Market Revenue Forecasts for Microbial Fermentation Submarket ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 4.6: Contract Biological Drug API Manufacturing Services Market Revenue Forecasts for Other APIs Expression Systems Submarket ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 5.1: Top Ten Best-Selling Drugs in 2018: Revenue ($bn)
  • Table 5.2: Contract API Biological Drug Revenue Forecasts ($bn), AGR (%), CAGR (%), by Therapeutic Area, 2018-2029
  • Table 5.3: Monoclonal Antibody Types and Sources
  • Table 5.4: Contract Biological Drug API Manufacturing Services Market Revenue Forecasts for Monoclonal Antibodies Submarket ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 5.5: The Four Classes of Next- Generation Antibody Therapies
  • Table 5.6: Contract Biological Drug API Manufacturing Services Market Revenue Forecasts for Vaccines Submarket ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 5.7: Comparison between biomanufacturing platforms for Vaccine Production: VLP
  • Table 5.8: Contract Biological Drug API Manufacturing Services Market Revenue Forecasts for Insulin Analogues Submarket ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 5.9: Contract Biological Drug API Manufacturing Services Market Revenue Forecasts for Interferon Therapies Submarket ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 5.10: Contract Biological Drug API Manufacturing Services Market Revenue Forecasts for Growth Hormones Submarket ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 5.11: Selected Long-Acting Growth Hormones in Development, 2018
  • Table 6.1: Contract Biological Drug API Manufacturing Market: Revenues ($bn) and Market Shares (%) by Region, 2018
  • Table 6.2: Contract Biological Drug API Manufacturing Market: Revenues ($bn) and Market Shares (%) by Submarket, 2018
  • Table 6.3: Contract API Biological Drug Revenue Forecasts ($bn), AGR (%), CAGR (%), by Region, 2018-2029
  • Table 6.4: Contract Biological Drug API Manufacturing Market: Leading Nationals Revenue Shares (%), 2018, 2024 & 2029
  • Table 6.5: EU and Switzerland Contract Biological Drug API Manufacturing: Revenue Forecasts ($bn), GAGR (%), AGR (%), 2018-2029
  • Table 6.6: EU and Switzerland Contract Biological Drug API Manufacturing: Revenues ($bn) and Shares (%) by Leading Country, 2018
  • Table 6.7: Germany Contract Biological Drug API Manufacturing Revenue Forecast ($bn), GAGR (%), AGR (%), 2018-2029
  • Table 6.8: UK Contract Biological Drug API Manufacturing Revenue Forecast ($bn), GARG (%), AGR (%), 2018-2029
  • Table 6.9: France Contract Biological Drug API Manufacturing Revenue Forecast ($bn), GARG (%), AGR (%), 2018-2029
  • Table 6.10: Switzerland Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
  • Table 6.11: Spain Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%),2018-2029
  • Table 6.12: Italian Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
  • Table 6.13: North America Contract Biological Drug API Manufacturing: Revenue Forecasts ($bn), GAGR (%), AGR (%), 2018-2029
  • Table 6.14: US Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
  • Table 6.15: Canada Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
  • Table 6.16: Mexico Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
  • Table 6.17: Contract Biological Drug API Manufacturing Market: BRIC National Revenue Forecasts ($bn), CAGR (%), AGR (%), 2018-2029
  • Table 6.18: BRIC Markets: API Revenues ($bn) and Market Shares (%), 2018
  • Table 6.19: Contract Biological Drug API Manufacturing Market: BRIC National Revenue Forecasts ($bn), CAGR (%), AGR (%), 2018-2029
  • Table 6.20: Chinese Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
  • Table 6.21: India Contract Biological Drug API Manufacturing Revenue Forecast ($bn), GAGR (%), AGR (%) 2018-2029
  • Table 6.22: Russia Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
  • Table 6.23: Brazilian Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
  • Table 6.24: Contract Biological Drug API Manufacturing Market: Other Leading Nationals Revenue Forecasts ($bn), CAGR (%), AGR (%), 2018-2029
  • Table 6.25: Japanese Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
  • Table 6.26: South Korean Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
  • Table 6.27: Selected Biotechs and Pharmaceutical Companies with Manufacturing Facilities in Singapore, 2019
  • Table 6.28: Singaporean Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
  • Table 7.1: Leading Biological drug API CMOs: Mammalian Cell Culture and Microbial Fermentation Manufacturing Scale, 2018
  • Table 7.2: Selected Other Biological drug API CMOs: Mammalian Cell Culture and Microbial Fermentation Manufacturing Scale, 2018
  • Table 7.3: Boehringer Ingelheim BioXcellence: Manufacturing Capacity, 2018
  • Table 7.4: Boehringer Ingelheim BioXcellence: Revenue ($bn), 2016-2018
  • Table 7.5: Celltrion Revenue ($bn), 2016-2018
  • Table 7.6: Lonza Pharma & Biotech Revenue ($bn), 2016-2018
  • Table 7.7: Samsung BioLogics CMO Revenue ($bn), 2016-2018
  • Table 7.8: Sandoz Biosimilar Pipelines: Selected Biosimilars, 2019
  • Table 8.1: Contract Biological Drug API Manufacturing Market: Strengths and Weaknesses, 2018
  • Table 8.2: Contract Biological Drug API Manufacturing Market: Opportunities and Threats, 2018-2029
  • Table 8.3: Biological Drug API Manufacturing Services Market: STEP Analysis, 2018
  • Table 8.4: Selected EU-Approved Biosimilars: Manufacturers and Companies, 2018
  • Table 8.5: Key Approved Next-Generation Antibody Therapies, 2018
  • Table 9.1: Contract Biological Drug API Manufacturing Market: Revenue Forecasts ($bn) by Expressions Submarket, 2019, 2021, 2023, 2025, 2027 and 2029
  • Table 9.2: Contract Biological Drug API Manufacturing Market: Revenue Forecasts ($bn) by Region, 2019, 2021, 2023, 2025, 2027 and 2029

List of Figures

  • Figure 1.1: Biological Drug API Manufacturing Services Submarkets 2018
  • Figure 2.1: Steps for Biological Drug Manufacturing, 2018
  • Figure 2.2: Contract API Manufacturing: Market Shares by Sector (%), 2018
  • Figure 2.3: Future Trends in the Biological Drug API Manufacturing Market, 2018-2029
  • Figure 3.1: Contract Biological Drug API Manufacturing Services Market: Revenue Forecast ($bn), AGR (%), 2018-2029
  • Figure 3.2: Contract Biological Drug API Manufacturing: Market Drivers
  • Figure 3.3: Contract Biological Drug API Manufacturing: Market Restraints
  • Figure 4.1: Contract Biological Drug API Manufacturing: Market Shares (%) by Expression Systems Submarket, 2018
  • Figure 4.2: Mammalian Cell Culture Submarket Forecast: Revenue ($bn), AGR (%), 2019-2029
  • Figure 4.3: Mammalian Cell Culture Submarket: Drivers and Restraints
  • Figure 4.4: Microbial Fermentation Submarket Forecast ($bn), AGR (%), 2019-2029
  • Figure 4.5: Microbial Fermentation Submarket: Drivers and Restraints, 2019
  • Figure 4.6: Other Expression Systems Submarket Forecast ($bn), AGR (%), CAGR (%), 2018-2029
  • Figure 5.1: Contract Biological Drug API Manufacturing: Market Shares (%) by Therapeutic Area Submarket, 2018
  • Figure 5.2: Monoclonal Antibodies Submarket Forecast: Revenue ($bn), AGR (%), 2018-2029
  • Figure 5.3: Vaccines Submarket Forecast, Revenue ($bn), AGR (%), 2018-2029
  • Figure 5.4: Insulin Analogues Submarket Forecast: Revenue ($bn), AGR (%), 2018-2029
  • Figure 5.5: Interferon Therapies Submarket Forecast, Revenue ($bn), AGR (%), 2018-2029
  • Figure 5.6: Growth Hormones Submarket Forecast, Revenue ($bn), AGR (%), 2018-2029
  • Figure 6.1: Contract Biological Drug API Manufacturing: Market Shares (%) by Region, 2018
  • Figure 6.2: Contract Biological Drug API Manufacturing: Market Shares by Leading Nationals (%), 2018
  • Figure 6.3: Contract Biological Drug API Manufacturing: Market Shares by Leading Nationals (%), 2024
  • Figure 6.4: Contract Biological Drug API Manufacturing: Market Shares by Leading Nationals (%), 2029
  • Figure 6.5: EU and Switzerland Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
  • Figure 6.6: EU Contract Biological Drug API Manufacturing: Leading National Revenue Shares (%), 2018
  • Figure 6.7: Germany Contract Biological Drug API Manufacturing Revenue Forecast ($bn), 2018-2029
  • Figure 6.8: UK Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
  • Figure 6.9: France Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
  • Figure 6.10: Switzerland Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
  • Figure 6.11: Spanish Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
  • Figure 6.12: Italian Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
  • Figure 6.13: North America Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
  • Figure 6.14: US Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
  • Figure 6.15: Canada Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
  • Figure 6.16: Mexico Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
  • Figure 6.17: Contract Biological Drug API Manufacturing Market: BRIC National Revenue Forecasts ($bn), AGR (%), 2018-2029
  • Figure 6.18: Biologics Market: BRIC Revenue Shares (%), 2018
  • Figure 6.19: Chinese Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
  • Figure 6.20: India Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
  • Figure 6.21: Russia Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
  • Figure 6.22: Brazilian Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
  • Figure 6.23: Japanese Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
  • Figure 6.24: South Korean Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
  • Figure 6.25: Singaporean Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
  • Figure 7.1: Leading Biological drug API CMOs: Mammalian Cell Culture Manufacturing Scale, 2018
  • Figure 7.2: Leading Biological drug API CMOs: Microbial Fermentation Manufacturing Scale, 2018
  • Figure 7.3: Boehringer Ingelheim BioXcellence: Revenue ($bn), 2016-2018
  • Figure 7.4: Celltrion Revenue ($bn), 2016-2018
  • Figure 7.5: Patheon N.V.: Revenue ($bn), 2014-2016
  • Figure 7.6: Lonza Pharma & Biotech Revenue ($bn), 2016-2018
  • Figure 7.7: Samsung BioLogics CMO Revenue ($bn), 2016-2018
  • Figure 9.1: Contract Biological Drug API Manufacturing Market: Revenue Forecasts ($bn) by Expressions Submarket, 2018-2029
  • Figure 9.2: Contract Biological Drug API Manufacturing Market: Revenue Forecasts ($bn) by Region, 2019, 2021, 2023, 2025, 2027 and 2029

COMPANIES LISTED:

  • Abasria
  • AbbVie
  • Accord Healthcare
  • Acquired Cedarburg Pharmaceuticals
  • Actavis Generics
  • Adaptimmune Therapeutics
  • Agensys
  • Althera Technologies
  • Altus Pharmaceuticals
  • Amgen
  • Apotex
  • Aptuit
  • arGEN-X
  • Ascendis Pharma A/S
  • Asterion
  • Astra Zeneca
  • Avid Bioservices Inc
  • Bakhu Pharma.
  • Banner Life Sciences
  • Basaglar
  • Baxalta
  • Baxter
  • Bayer
  • Bever Pharmaceutical
  • Biocad
  • Biocon
  • Biogen
  • Biogen Idec
  • BMS
  • Boehringer Ingelheim
  • Boehringer Ingelheim BioXcellence
  • Bolder BioTechnology
  • Calico Life Science
  • Caspugel
  • Catalent Biologics
  • Celgene
  • Celldex Therapautics
  • Celltrion
  • Cinfa
  • CMC Biologics
  • CMIC Holdings Co. Ltd.
  • CMO Relthy Laboratórios
  • Cook Pharmica
  • Critical Pharmaceuticals
  • CT Arzneimittel
  • Cytos Biotechnology
  • Cytovance Biologics
  • DPx Fine Chemicals
  • DPx Holdings B.V.
  • DSM Biologics
  • DSM Sinochem Pharmaceuticals
  • Eli Lily
  • EMD Millipore
  • FDA
  • Ferring Pharmaceuticals
  • Filnox Biotech
  • Fresenius
  • Fujifilm Diosynth Biotechnologies
  • Gallus BioPharmaceuticals,
  • GE Healthcare
  • Genentech
  • GeneScience Pharmaceuticals Co., Ltd.
  • Genexine and Handok
  • Genmab
  • Genzyme
  • Germany's Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
  • Gilead Sciences, Inc.
  • GSK
  • Hanmi Pharmaceutical Co.
  • Hexal
  • Index Ventures
  • Infarco
  • Infinity Pharmaceuticals
  • Inno Biologics
  • Innovation Network Corporation of Japan (INCJ),
  • Japanese Ministry of Health, Labour and Welfare
  • Johnson and Johnson
  • Johnson Matthey
  • JSR Corporation
  • Kalon Biotherapeutics
  • KBI Biopharma, Inc.
  • Kemwell
  • Kyowa Hakko Kirin
  • Labrys Biologics Inc,
  • Laureate Biopharma
  • LG Life Sciences, Ltd.
  • Lonza
  • Matrix Laboratories
  • Merck
  • Mitsubishi Gas Chemical Company
  • Mylan
  • Neopharm
  • NHS
  • NICE
  • Nikon
  • Nippon kayaku
  • Norbitec
  • Novartis
  • Novasep
  • Novo Nordisk
  • Nuron Biotech
  • Nycomed
  • Opko Health
  • Patheon
  • PelChem
  • Peregrine Pharmaceuticals
  • Perrigo
  • Pfizer
  • Pharmstandard
  • Phyton Biotech
  • Piramal Healthcare
  • Precision Biologics
  • Progenics
  • Quintiles
  • Rebtschler Biotechnologie
  • Recepta Biopharma
  • Redwood Bioscience
  • Rentschler
  • Rentschler Biotechnologie
  • Roche
  • RoYal DSM
  • SAFC
  • Samsung BioLogics
  • Sanofi
  • SCM Pharma
  • Seattle Genetics
  • ShangPharma
  • SICOR Biotech
  • Sigma-Aldrich Corporation
  • Stada
  • SunShine Biopharma
  • SynCo BioPartners
  • Takeda
  • Teva
  • Therapure Biopharma
  • Thermo Fisher
  • Toyobo Biologics
  • Transgene SA
  • Versartis
  • Vertex
  • Vida Pharma
  • VTU
  • WHO
  • WuXi Biologics,
  • WuXi PharmaTech
  • Zhangjiang Biotech
  • Zhejiang Jiang Yuan Tang Biotechnology
  • ZJ Base